Teriparatide Sun



This medicine is authorised for use in the European Union.


Teriparatide Sun is a medicine used to treat adults with osteoporosis (a disease that makes the bones fragile) in women who have been through menopause and in men who are at an increased risk of fractures. The medicine is also used to treat osteoporosis in men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid). 

Teriparatide Sun is a ‘hybrid medicine’, meaning that it is similar to a ‘reference medicine’ containing the same active substance, but there are certain differences between the two. The reference medicine for Teriparatide Sun is Forsteo, in which the active substance is of biological origin (produced using bacteria), whereas in Teriparatide Sun it is chemically synthesised.

Teriparatide Sun contains the active substance teriparatide. 

This EPAR was last updated on 12/12/2022

Authorisation details

Product details
Teriparatide Sun
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Osteoporosis
  • Osteoporosis, Postmenopausal
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Sun Pharmaceutical Industries Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Polarisavenue 87
2132JH Hoofddorp
The Netherlands

Product information

18/11/2022 Teriparatide Sun - EMEA/H/C/005793 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Teriparatide SUN is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).

Assessment history

How useful was this page?

Add your rating